

1 **Multi-omics Analysis of Umbilical Cord Hematopoietic Stem Cells from a Multi-ethnic**
2 **Cohort of Hawaii Reveals the Transgenerational Effect of Maternal Pre-Pregnancy Obesity**

3

4 Yuheng Du¹, Paula A. Benny², Yuchen Shao³, Ryan J. Schlueter², Alexandra Gurary², Annette
5 Lum-Jones⁴, Cameron B Lassiter⁴, Fadhl M. AlAkwa⁵, Maarit Tiirikainen⁴, Dena Towner², W.
6 Steven Ward², Lana X Garmire^{1*}

7

8 1. Department of Computational Medicine and Bioinformatics, University of Michigan, Ann
9 Arbor, MI

10 2. Department of Obstetrics and Gynecology, University of Hawaii, Honolulu, HI

11 3. Department of Electrical Engineering and Computer Science, University of Michigan, Ann
12 Arbor, MI

13 4. University of Hawaii Cancer Center, Population Sciences of the Pacific Program-
14 Epidemiology, Honolulu, HI

15 5. Department of Neurology, University of Michigan, Ann Arbor, MI

16 *. Corresponding author email: lgarmire@med.umich.edu

17

18 **Keywords: obesity, Native Hawaiian, Hematopoietic stem cells, Multi-omics, cord blood,**
19 **methylation, pregnancy**

20

- 21 **Abbreviation:**
- 22 **BH:** Benjamini-Hochberg
- 23 **BMI:** Body mass index
- 24 **C:** Acylcarnitines
- 25 **DE:** Differential expression
- 26 **DIABLO:** Data Integration Analysis for Biomarker discovery using Latent cOmponents
- 27 **DM:** Differential methylation
- 28 **DMR:** Differentially methylated regions
- 29 **DOHaD:** Developmental Origins of Health and Disease
- 30 **EWAS:** Epigenome-wide association studies
- 31 **FC:** Fold Change
- 32 **FDR:** False positive results
- 33 **KEGG:** Kyoto Encyclopedia of Genes and Genomes
- 34 **LOG:** Logistic regression
- 35 **PANDA:** Preferential Attachment-based common Neighbor Distribution derived Associations
- 36 **PC aa:** Diacyl phosphatidylcholines
- 37 **PC ae:** Acyl-alkylphosphatidylcholines
- 38 **PCC:** Pearson correlation coefficients
- 39 **PPI:** Protein-Protein Interaction
- 40 **RBF:** Radial Basis Function
- 41 **RF:** Random Forest
- 42 **RPART:** Recursive Partitioning and Regression Trees
- 43 **SOV:** Source of variance

- 44 **SVD:** Singular value decomposition
- 45 **SVM:** Supportive Vector Machine
- 46 **kNN:** k-Nearest Neighbour
- 47 **TSS:** Transcription start site
- 48 **uHSCs:** Umbilical cord blood hematopoietic stem cells
- 49 **UMAP:** Uniform Manifold Approximation and Projection
- 50 **VLCAD:** Very long-chain acyl-CoA dehydrogenase
- 51 **WGCNA:** Weighted Gene Co-expression Network Analysis

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67 **Abstract**

68 **Background:** Maternal obesity is a health concern that may predispose newborns to a high risk
69 of medical problems later in life. To understand the transgenerational effect of maternal obesity,
70 we conducted a multi-omics study, using DNA methylation and gene expression in the
71 CD34+/CD38-/Lin- umbilical cord blood hematopoietic stem cells (uHSCs) and metabolomics
72 of the cord blood, all from a multi-ethnic cohort (n=72) from Kapiolani Medical Center for
73 Women and Children in Honolulu, Hawaii (collected between 2016 and 2018).

74 **Results:** Differential methylation (DM) analysis unveiled a global hypermethylation pattern in
75 the maternal pre-pregnancy obese group (BH adjusted $p < 0.05$), after adjusting for major clinical
76 confounders. Comprehensive functional analysis showed hypermethylation in promoters of
77 genes involved in cell cycle, protein synthesis, immune signaling, and lipid metabolism.

78 Utilizing Shannon entropy on uHSCs methylation, we discerned notably higher quiescence of
79 uHSCs impacted by maternal obesity. Additionally, the integration of multi-omics data-including
80 methylation, gene expression, and metabolomics-provided further evidence of dysfunctions in
81 adipogenesis, erythropoietin production, cell differentiation, and DNA repair, aligning with the
82 findings at the epigenetic level. Furthermore, the CpG sites associated with maternal obesity
83 from these pathways also predicted highly accurately (average AUC = 0.8687) between cancer
84 vs. normal tissues in 14 cancer types in The Cancer Genome Atlas (TCGA).

85 **Conclusions:** This study revealed the significant correlation between pre-pregnancy maternal
86 obesity and multi-omics level molecular changes in the uHSCs of offspring, particularly in DNA
87 methylation. Moreover, these maternal obesity epigenetic markers in uHSCs may predispose
88 offspring to higher cancer risks.

89

90 **Introduction**

91 Maternal obesity has emerged as a primary health concern during pregnancy, with its prevalence
92 alarmingly increasing. According to a study by the Centers for Disease Control and Prevention,
93 the percentage of women experiencing pre-pregnancy obesity in the United States escalated from
94 26% to 29% between 2016 and 2019 ¹. Born to mothers with obesity, higher birth weight is
95 associated with a higher incidence of childhood cancers such as leukemia and neuroblastoma ^{2,3},
96 as well as greater risks of prostate and testicular cancers in men ⁴⁻⁶ and breast cancer in women ⁷.
97 Moreover, maternal obesity may have a transgenerational effect and set the stage for increased
98 chronic disease susceptibility later in the adulthood of offspring ^{8,9}. The hypothesis of the utero
99 origin of diseases proposes that numerous chronic diseases have their origins in the fetal stage,
100 the earliest phase of human development ^{10,11}. Some researchers have speculated higher stem cell
101 burdens in newborn babies born from obese mothers ¹². Altered hormonal environment and
102 nutrient availability can induce critical changes in fetal stem cells ¹³, which may predispose these
103 cells to malignant transformation, aligning with the idea of the cancer stem cell hypothesis that
104 cancer cells have stem cell-like properties with an uncontrolled self-renewal program ¹⁴⁻¹⁶. In
105 particular, a study showed increases in cord blood CD34+CD38- stem cell and CD34+
106 progenitor cell concentrations with maternal obesity ¹⁷, suggesting that the higher proportions of
107 stem cells in cord blood may make the babies more susceptible to obesity and cancer risks.
108 However, so far little work provides the direct molecular links as to how maternal obesity affects
109 cellular function and increases the disease risk in offspring.
110 To seek answers in this area, we conducted an epigenome-centered multi-omics study to directly
111 pinpoint the effect of maternal obesity in umbilical cord blood hematopoietic stem cells
112 (uHSCs). Epigenetics is chosen as the center of multi-omics integration, as it is both inheritable

113 and susceptible to modification by diseases. Thus, it may serve as a plausible mediator in the
114 transmission of the effects of maternal obesity to offspring. We incorporate gene expression for
115 cord blood stem cells and metabolomics data from the cord blood serum as the downstream
116 readout of epigenetics changes. By elucidating these molecular connections, we provide a
117 systematic understanding of how maternal obesity during pregnancy can influence the multiple
118 types of molecular profiles of newborns. Such knowledge may ultimately help develop early
119 therapeutic interventions at the molecular level to mitigate these transgenerational health risks
120 due to maternal obesity.

121

122

123 **Methods**

124

125 **Overview of the maternal pre-pregnancy cohort with baby cord blood**

126 In this study, baby cord blood samples from 72 pregnant women (34 obese; 38 non-obese) who
127 delivered at Kapiolani Medical Center for Women and Children in Honolulu, Hawaii (2015-
128 2018) were collected. The study was approved by the Western IRB (WIRB Protocol
129 #20151223). Patients meeting the inclusion criteria were identified from pre-admission medical
130 records with pre-pregnancy BMI ≥ 30.0 (maternal obesity) or 18.5-25.0 (normal weight).
131 Pregnant women undergoing elected C-sections at ≥ 37 weeks gestation were included, to
132 minimize confounding events during the labor. Patient exclusion criteria included pregnant
133 women with preterm rupture of membranes, labor, multiple gestations, pregestational diabetes,
134 hypertensive disorders, cigarette smokers, infection of human immunodeficiency virus or
135 hepatitis B virus, and chronic drug use. Demographic and phenotypic information was recorded,

136 including maternal and paternal age, ethnicity, gestational weight gain, gestational age, parity,
137 and gravidity. For newborns, Apgar scores were documented at 1 minute and 5 minutes post-
138 delivery. The Apgar score serves as a comprehensive assessment of a newborn's health, with a
139 normal range considered to be between 7 to 10¹⁸.

140

141 **Sample preparation and methylation profiling**

142 The baby cord blood sample was collected in the operating room under sterile conditions at the
143 time of the C-section (Pall Medical Cord Blood Collection Kit containing 25ml citrate phosphate
144 dextrose). The umbilical cord was first cleansed with chlorhexidine swabs before cord blood
145 collection. The total volume of collected blood was measured and recorded before aliquoting to
146 conical tubes for centrifugation. The tubes were centrifuged at 200g for 10 min, and plasma was
147 collected. The plasma volume was replaced with 2% FBS/PBS. Negative selection reagents were
148 added to the blood and incubated for 20 min (Miltenyi Biotec, Auburn, CA). The cord blood was
149 diluted with an equal volume of 2% FBS/PBS. A 20ml aliquot of the diluted blood was layered
150 over a density gradient (15ml Lymphoprep) and centrifuged at 1200g for 20 min. The top layer
151 containing an enriched population of stem cells was collected, centrifuged at 300g for 8 min, and
152 then washed in 2% FBS/PBS. Red blood cells were lysed using ammonium chloride (9:1) with
153 incubation on ice for 10 min, washed twice, and then resuspended in 100 μ l of 2% FBS/PBS.

154 Cells were stained with Lineage FITC and CD34 APC for 45 min on ice, washed twice, and then
155 sorted using the BD FACS Aria III. Hematopoietic stem cells (CD34⁺/CD38⁻/Lin⁻) were collected
156 and stored at -80°C until DNA/RNA extraction.

157 DNA and RNA were extracted simultaneously using the AllPrep DNA/RNA extraction kit
158 (Qiagen). DNA purity and concentration were quantified in Nanodrop 2000 and Picogreen assay.

159 Bisulfite conversion of 500 ng DNA was performed using the EZ DNA Methylation kit (Zymo),
160 followed by sample processing for Infinium HumanMethylation450 bead chips (Illumina)
161 according to the manufacturer's instructions. Bead chips were analyzed at the Genomics Shared
162 Resource at the University of Hawaii Cancer Center.

163

164 **Bulk RNA sequencing**

165 A total of 50 RNA samples were prepared for bulk RNA Sequencing. RNA concentration and
166 RIN score were assayed using Nanodrop 2000 and Agilent Bioanalyzer. A total of 200 ng of
167 high-quality RNA ($RIN \geq 7$) was subjected to library construction (polyA) and sequenced on
168 HS4000 (2x100) at the Yale Center for Genome Analysis, Connecticut to obtain at least 25M
169 paired reads per sample.

170

171 **Methylation data pre-processing**

172 R version 3.6.3 was used for all downstream analyses. Raw intensity data (.idat) were extracted
173 using the 'ChAMP' package (version 2.16.2) in R¹⁹⁻²². Quality control and processing were
174 performed following the ChAMP pipeline. Background controls were subtracted from the data,
175 and raw data that did not pass detection P-value of 0.05 were removed. For each CpG site, the
176 methylation score was initially calculated as the beta value, a fluorescence intensity ratio
177 between 0 and 1. CpG sites whose probes had known underlying SNPs and association with XY
178 chromosomes were removed from analysis due to potential confounding. After BMIQ
179 normalization²³, the batch effect due to non-biological technical variation caused by experiment
180 handling was removed using the ComBat function in the ChAMP package, confirmed by the
181 singular value decomposition (SVD) plot. The M-values for differential analysis were

182 transformed from beta-values using lumi (ver 3.1.4) in R²⁴⁻²⁷. A total of 410,765 CpG sites
183 remained for downstream analysis after probe filtering, normalization, and batch removal.

184

185 **Source of variation analysis and confounding adjustment**

186 To eliminate potential confounding factors of pre-pregnant maternal obesity among the 13
187 clinical factors, we conducted a source of variation analysis to identify the clinical factors that
188 significantly contribute to the methylation level variation, as done before^{28,29}. The variables with
189 F statistics greater than 1 (the error value) were determined as confounders and subjected to
190 confounding adjustment. These factors include the baby's sex, net weight gain during the
191 pregnancy, maternal age, maternal ethnicity, paternal ethnicity, gravidity, and gestational age. To
192 adjust for confounding, a linear regression model is built using the 'limma' package to fit
193 methylation M values of each CpG site, using the confounding factors above. The remaining
194 residuals on the M values were considered to be confounding-adjusted for the subsequent
195 bioinformatics analysis of DNA methylation.

196

197 **Bioinformatics analysis of differential methylation (DM)**

198 A moderated t-test from the 'limma' R package (version 3.42.2)³⁰ was used for detecting DM
199 CpG sites between healthy controls and cases with M values. The p-values were adjusted for
200 multiple hypotheses testing using Benjamini-Hochberg FDR. CpG sites with FDR <0.05 were
201 considered statistically significant. To minimize the effect of the gestational age, CpG sites
202 located within the gestational-age-related differentially methylated regions (DMR) were
203 removed. A total of 130 DMRs related to gestational age were identified using linear regression
204 analysis performed with bumphunter³¹ across eight public datasets including a total of 248

205 patients.: GSE31781³², GSE36829³³, GSE59274^{32,34}, GSE44667³⁵, GSE74738³⁶, GSE49343
206³⁷, GSE69502³⁸, and GSE98224^{39,40}. The complete list of DMRs was included in
207 **Supplementary Table 1**. Hypermethylation and hypomethylation states were defined by the
208 values of log₂ Fold Change (log₂FC) of M values in cases compared to controls:
209 hypermethylation if bigger than 0, and hypomethylation if less than 0. Corresponding genes and
210 feature locations of these differential CpG sites were annotated using
211 IlluminaHumanMethylation450kanno.ilmn12.hg19 (ver 0.6.0)⁴¹.

212

213 **KEGG pathway enrichment analysis**

214 ‘gometh’ function from R package “missMethyl” (version 1.26.1)^{42–45} was used for KEGG
215 pathway enrichment^{46–48} with DNA methylation data. DM sites were used for pathway
216 enrichment within five supergroups from KEGG pathways: Metabolism, Genetic Information
217 Processing, Environmental Information Processing, Cellular Processes, and Organismal Systems.
218 Pathways with adjusted p-values less than 0.05 were considered significant. Pathway scores for
219 protein pathways (KEGG: Transcription, Translation, Folding, sorting and degradation) and
220 immune pathways (KEGG: Immune system) were calculated with averaged beta values from the
221 promoter region CpG sites.

222

223 **Weighted co-expression network analysis**

224 Firstly, we adjusted all beta values with clinical confounders, then summarized the DM CpG
225 sites at the gene level by averaging the beta values in the promoter regions (those in the TSS200
226 and TSS1500 promoter regions). Next, we transformed adjusted beta values to adjusted M values
227 for the downstream adjacency matrix construction. We used adjusted M values for the weighted

228 gene co-expression network analysis (WGCNA) with R package ‘WGCNA’ (version 1.70-3)
229 ^{49,50}. The soft threshold for the weighted adjacency matrix with an adjusted $R^2 > 0.8$ was 7. The
230 topological overlap matrix was constructed for hierarchical clustering. Modules were identified
231 by the dynamic tree-cut algorithm. The networks were exported to Cytoscape with an edge
232 weight greater than 0.03 in each module. The genes with the highest betweenness and degree in
233 the WGCNA network were identified as the hub genes for different modules.

234

235 **Protein-protein interaction network analysis**

236 For the protein-protein interaction (PPI) network analysis, DM genes are used as the inputs and
237 were mapped on the STRING database (version 10) ⁵¹. Significantly functionally associated
238 protein pairs were identified using PANDA (Preferential Attachment based common Neighbor
239 Distribution derived Associations) (version 0.9.9) ⁵². KEGG pathways associated with these
240 protein pairs (in terms of genes) were found using PANDA. The bipartite network graph was
241 visualized using Cytoscape (version 3.8.1) ⁵³.

242

243 **Stemness score computation**

244 The stemness score was based on Shannon entropy and scaled plasticity, as proposed previously
245 ⁵⁴. Shannon entropy has been widely applied in developmental biology, particularly in stem cell
246 research ⁵⁵⁻⁵⁷. The formulas are shown below:

$$Entropy = \sum_{i=1}^N \frac{-\frac{CpG_i}{N} \log\left(\frac{CpG_i}{N}\right)}{\log(N)}$$

$$StemnessScore = \frac{Entropy - \min(Entropy)}{\max(Entropy) - \min(Entropy)}$$

247

248 N is the total number of CpG sites. CpG is represented by the beta value on each CpG probe.

249 The stemness score was calculated for all samples using all remaining 410,765 CpG sites after
250 the preprocessing. A Wilcoxon rank test was performed between the stemness scores of the
251 healthy and maternally obese groups.

252

253 **Bulk RNA-seq data processing**

254 The Illumina universal adapter regions of raw RNA-seq data were first trimmed using BMAP
255 (version 38.91)⁵⁸. All raw sequences passed the quality control using fastqc (version 0.11.8)⁵⁹.

256 The trimmed .fastq files were aligned by STAR (version 2.7.0f)⁶⁰ to the human Ensembl
257 genome (Homo_sapiens.GRCh38.dna.primary_assembly.fa) and Ensembl annotation

258 (Homo_sapiens.GRCh38.94.gtf). The gene expression counts were calculated using featureCount

259 ⁶¹ from Subread (ver 1.6.4)⁶².

260

261 **Differential expression (DE) of RNA-Seq data**

262 The statistically significant DE genes between healthy controls and maternally obese cases were
263 found adjusting for the same clinical confounders for methylation analysis using the 'DESeq2'

264 (version 1.26.0)⁶³ and 'limma-voom' function from 'limma' package³⁰. The p-values were

265 adjusted for multiple hypotheses testing using BH adjustment. Genes with adjusted p-values less

266 than 0.05 were considered statistically significant.

267

268 **Correlation analysis between bulk RNA-seq and methylation data**

269 A subset of 47 patients have done both methylation and RNA-seq assays. Differential expression

270 analysis was done on the bulk RNA-seq data using the 'limma' package, with a threshold of BH

271 adjusted $p < 0.05$ to be differential genes. Pearson correlation coefficients (PCC) were calculated
272 between gene expression and methylation beta values from the promoter regions, among the
273 same patients. As mostly a negative correlation between gene expression and DNA methylation
274 in the promoter region is expected, genes with a high negative correlation ($PCC < -0.2$) were used
275 for pathway enrichment using TOPPFUN⁶⁴⁻⁶⁶. Top genes of interest were selected with the
276 absolute value Fold Change > 1.5 in gene expression and gene-methyl correlation < -0.3 for hyper-
277 and hypo-methylated CpG sites.

278

279 **Metabolomics analysis**

280 Metabolomics data were acquired from a previously published study involving 87 patients in the
281 same cohort from three batches (metabolomics workbench study ID ST001114)⁶⁷. Targeted
282 metabolites were generated with LC-MS, and untargeted metabolites were generated with GC-
283 MS. After the removal of compounds missing in more than 10% of samples, a total of 185
284 metabolites remained, including 10 amino acids (AA), 40 acylcarnitines (C), 35 acyl/acyl
285 phosphatidylcholines (PC aa), 38 acyl/alkyl phosphatidylcholines (PC ae) and 62 untargeted
286 metabolites. The raw metabolite data were log-transformed, standardized, normalized using
287 variance stabilization normalization (VSN), and batch corrected with ComBat function in *sva*
288 package⁶⁸. Differential metabolites were identified by *limma*, with clinical confounders
289 adjustment.

290

291 **Multi-omics integration on metabolomics, epigenomics, and transcriptomics**

292 A subset of 42 patients have the matched methylation, gene expression, and metabolomics data.
293 We applied multi-omics integration with Data Integration Analysis for Biomarker discovery

294 using Latent cOmponents (DIABLO) implemented in the mixOmics package⁶⁹. DIABLO finds
295 the correlated consensus latent variables among different omics in the supervised manner. Top
296 DIABLO features for each omic were selected based on the loading values. We integrated the
297 pathway-level methylation, gene, and metabolite interaction using pathview⁷⁰.

298

299 **Evaluation of maternal pre-pregnancy obesity biomarkers in cancer prediction**

300 We collected Infinium HumanMethylation450 data for a total of 14 cancer datasets (adjacent
301 normal samples > 10): BLCA, BRCA, COAD, ESCA, HNSC, KIRC, KIRP, LIHC, LUAD,
302 LUSC, PAAD, PRAD, THCA, UCEC from The Cancer Genome Atlas (TCGA data portal:
303 <https://portal.gdc.cancer.gov/>). In total, 6428 samples were obtained, consisting of 5715 tumor
304 samples and 713 adjacent normal tissues. To build the TCGA cancer classification model with
305 maternal obesity biomarkers, we selected 186 hypermethylated CpG sites from the promoter
306 regions of the genes involved in the top five significant pathways based on the missMethyl
307 KEGG enrichment results. This includes cell cycle, ribosome, nucleocytoplasmic transport,
308 ribosome biogenesis in eukaryotes, and mTOR signaling pathway.

309 To handle imbalanced data, we randomly down sampled tumor samples to match the number of
310 adjacent normal samples with twenty repetitions for each cancer using the ‘downSample’
311 function from ‘caret’ R package⁷¹. We split the training and testing samples at a ratio of 80/20
312 for each augmented dataset. We constructed five classification models with 5-fold cross-
313 validation using ‘caret’ R package⁷¹, including logistic regression (LOG), Random Forest (RF),
314 Supportive Vector Machine (SVM) with Radial Basis Function (RBF) kernel, GLMNET, and k-
315 Nearest Neighbour (kNN). We report accuracy, sensitivity, specificity, and F1 score for model
316 performance as done before⁷².

317

318 **Results**

319

320 **Overview of study design and cohort characteristics**

321 This study aims to investigate the transgenerational effect of pre-pregnancy maternal obesity on
322 offspring. A total of 72 patients who elected to deliver full-term babies through C-sections were
323 recruited from Kapiolani Medical Center for Women and Children in Honolulu, Hawaii from
324 2016 to 2018. Among them, 38 deliveries are in the healthy control group and 34 are cases with
325 pre-pregnancy maternal obesity. We excluded natural virginal births, to avoid its potential
326 confounding effect on multi-omics profiles. We also carried out stringent recruitment selection
327 criteria, including matching the mothers' ages as much as possible, as well as similar net
328 gestational weight gain to minimize its confounding effect over maternal pre-pregnancy maternal
329 obesity. The overall study design is shown in **Figure 1**. Briefly, upon collecting the blood
330 samples, umbilical cord blood hematopoietic stem cells (uHSCs) were enriched by FACS sorting
331 with CD34+CD35-LIN- markers (see **Methods**). We extracted DNA and RNA from these
332 uHSCs for Illumina 450k array based DNA methylation and bulk RNA-Seq sequencing
333 respectively. The plasma from these cord blood samples was subject to untargeted metabolomics
334 assays using GC-MS and targeted metabolomics assays using LC-MS⁶⁷. Given the rationale
335 that DNA methylation could be the mediator for exerting the transgenerational effect of maternal
336 obesity^{73,74}, we carried out multi-omics data integration analysis in the DNA methylation-centric
337 manner.

338

339 The demographic details and clinical information of these patients are summarized in **Table 1**.
340 The distributions of the most representative variables are shown in **Figure 2**. Among categorical
341 demographic variables, the distribution of baby sex had no statistical difference between obese
342 and health groups, whereas the ethnicity distributions among mothers and fathers, parity and
343 gravidity are statistically different ($P < 0.05$) between the two groups (**Figure 2A-2E**). Besides
344 maternal pre-pregnancy BMI, other maternal parameters such as maternal age, gestational week,
345 net weight gain and hemoglobin are also not statistically significantly different between the two
346 groups per study design (**Figure 2F-2I, Table 1**). While mothers of Asian ethnicity are the
347 majority in the control group, NHPs account for the majority of the maternal-obese group,
348 revealing the health disparity issue known in the state of Hawaii⁷⁵. Moreover, the control group
349 has lower parities and gravidities, compared to the cases. Babies born to obese mothers show
350 significantly higher ($P < 0.05$) body weights compared to the control group, as expected⁷⁶. Other
351 parameters including the baby gender, head circumference, body length, and APGAR score at 5
352 min after birth are not statistically significantly different between case and control groups
353 (**Figure 2J-2M**).

354

355 **Global hypermethylation pattern revealed by CpG level methylation analysis**

356 For scientific rigor, it is critical to adjust for confounding in DNA methylation association
357 analysis⁷⁷. Thus we performed the source of variance (SOV) analysis on the beta values of the
358 DNA methylation with respect to physiological and phenotypic information, in order to assess
359 potential confounding factors systematically^{28,29,77}. As shown in **Figure 3A**, marginal F-
360 statistics in the SOV analysis show that the dominating contribution to DNA methylation
361 variation is maternal pre-pregnancy obesity status, confirming the quality of the study design

362 which aimed to minimize other confounders' effect. The other minor confounding factors
363 include baby sex, maternal age, maternal ethnicity, net weight gain during pregnancy, paternal
364 ethnicity, gravidity, and gestational age (F-statistics>1). After adjusting these factors by linear
365 regression, all have reduced F-statistics of less than 0.5 (**Figure 3B**) except maternal pre-
366 pregnancy obesity, confirming the success of confounding removal.

367 Next, we conducted differential methylation (DE) analysis on the confounding adjusted DNA
368 methylation data (**Methods**). We observed a global hypermethylation pattern in pre-pregnancy
369 obese samples, with 10,254 hypermethylated vs. 5394 hypomethylated CpG sites (**Figure 3C**).
370 The top 20 differentially hypermethylated and hypomethylated CpG sites are reported in **Table**
371 **2**, respectively. These CpG sites are related to a wide variety of biological functions, including
372 inflammation (CD69, ADAM12), transcription factors (ZNF222, HMG4, LHX6, TAF3),
373 proliferation and apoptosis (HDAC4, DHRS4, LRCH3, SAFB2, CRADD, EBF3, PRKAR1B).
374 Some top DM CpG sites are directly associated with obesity, including HDAC4⁷⁸ and PLEC1⁷⁹.
375

376 We further examined the distributions of these differentially methylated sites, relative to the CpG
377 island regions and promoter proximity. (**Figure 3D-E**). A big fraction (38.7%) of the DM sites
378 are located in CpG islands^{80,81}, significantly higher than that from the Illumina 450K annotation
379 (P<2E-16). CpG islands are more frequent in the hypermethylated sites (41.3%) than in the
380 hypomethylated sites (33.6%), which is consistent with the global hypermethylation pattern.
381 Relative to gene localization, DM sites are most frequent (32.1%) in the promoter regions
382 (including 16.8% and 15.3% in TSS200 and TSS1500 respectively) as expected.
383

384 **Functional analyses reveal the association between maternal obesity and cell cycle, immune**
385 **function and metabolic changes in the cord blood of offspring**

386 To investigate the biological functions related to the epigenome alternation, we conducted
387 systematic analysis of DM sites employing multiple methods: KEGG pathway enrichment
388 analysis, Weighted Gene Co-expression Network Analysis (WGCNA), and Protein-Protein
389 Interaction (PPI) network analysis.

390

391 KEGG pathway enrichment analysis on hypermethylated CpG sites identified five significant
392 pathways with $FDR < 0.05$ (**Figure 4A**), including the cell cycle, ribosome, nucleocytoplasmic
393 transport, ribosome biogenesis in eukaryotes, and mTOR signaling pathway. Cell cycle,
394 ribosome, and nucleocytoplasmic transport pathways are essential to normal cell functioning.
395 mTOR signaling pathway coordinates the nutrient-mediated metabolism, immune responses and
396 cell cycle progression, and dysregulation of mTOR could lead to various diseases such as cancer
397 and obesity⁸². There was no significantly enriched pathway emerging from hypomethylated
398 CpG sites. The maternally obese group shows significantly higher methylation levels in KEGG
399 protein synthesis and immune system pathway collections compared to the control group,
400 indicating repression in immune response as well as translation and protein synthesis (**Figure**
401 **4B-C**). Similarly, we further explored the differential potential, or stemness, of umbilical cord
402 Hematopoietic Stem Cells (uHSCs). We first confirmed the homogeneity of uHSCs by single-
403 cell RNA sequencing UMAP plot (**Supplementary Figure 2**). We calculated the cell stemness
404 scores using the DNA methylation beta values similar to others⁸³. uHSCs derived from the
405 maternally obese group exhibit significantly elevated stemness scores ($P < 0.01$) in comparison to
406 the control group (**Figure 4D**), confirming the results in KEGG pathway analysis.

407
408 Next, we applied WGCNA to cluster co-regulation of gene-level methylation, by averaging CpG
409 sites to affiliated genes (see **Methods**). Five co-expression modules are identified, using the M-
410 values adjusted for clinical confounders (**Supplementary Figure 1A**), and all modules show
411 positive correlations with maternal obesity except one. The largest turquoise module (**Figure 4E**)
412 is related to cell cycle, protein synthesis, and transport and vesicle trafficking pathways through
413 pathway enrichment analysis. Some hub genes in this module are identified, including INTU,
414 ANAPC7, and AGBL5. These genes were reported essential for maintaining cell polarity
415 (INTU)⁸⁴, proliferation (ANAPC7)⁸⁵ and glycemc control (AGBL5)⁸⁶. The brown module
416 (**Figure 4F**) is enriched with immune response pathways, in which TLR6 is identified as a hub
417 gene. The other yellow module is related to ion homeostasis, and the gray module is related to
418 the p53 pathway, apoptosis, cell senescence, and ER stress (**Supplementary Figure 1B**). The
419 only negatively correlated blue module is associated with axon guidance and VEGF signaling
420 pathway (**Supplementary Figure 1B**).

421
422 Furthermore, we examined the PPI network, using the gene-level DNA methylation as surrogates
423 (**Figure 4G**). The PPI analysis identifies 14 unique pathways (FDR < 0.05) predominantly
424 associated with hypermethylated CpG sites in the TSS200 and TSS1500 regions. The top five
425 largest pathways included ribosome, proteasome, cell cycle, axon guidance, RNA polymerase,
426 and neuroactive ligand-receptor interaction. Taken all three types of systematic analyses
427 together, cell cycle, immune function and protein synthesis are ubiquitously highlighted,
428 suggesting that these biological functions in cord blood stem cells are negatively impacted by
429 maternal obesity.

430

431

432 **Multi-omics analysis reveals disruptions in cell cycle and metabolic pathways**

433 To systematically investigate the epigenetic, transcriptomic, and metabolomic alterations
434 induced by maternal obesity, we performed multi-omics integration analysis on this cohort. We
435 employed DIABLO, a supervised integration method that extracts features associated with
436 maternal obesity, based on the correlations in the embedding space⁶⁹. **Figure 5A-C** shows that
437 methylation data provide the clearest separation between obese and control groups, confirming
438 the value of the earlier DNA methylation-centered analysis.

439

440 The top 25 features from each omic with the highest feature weights (loadings) following
441 integrated canonical correlation analysis are demonstrated in **Figure 5D-F**. The methylation
442 features with the highest weights related to maternal obesity include CpG sites involved in cell-
443 cycle control, glucose metabolism, and adipogenesis (FOXO1⁸⁷), DNA repair (LIG3, SMUG1),
444 erythropoietin pathway and differentiation (EPO, CSNK2A1, CSF1), which are hypermethylated
445 in the obese group. Hypomethylation of LEP (encoding leptin) was also observed as a top
446 feature, aligning with prior findings that maternal obesity is associated with elevated maternal
447 leptin levels, a known marker of adipose tissue⁸⁸. These featured CpG sites indicate repression
448 in fat metabolism and DNA repair and reduced differentiation potential. In the transcriptomic
449 space, many genes related to mRNA splicing (SRRM1, IGF2BP1, IGF2BP2, CNOT4) have
450 increased expression levels due to maternal obesity. Among the metabolite features, essential
451 sugars (glucose, xylose), poly-unsaturated fatty acids (oleic acids, DHA, arachidonic acid), and
452 phosphatidylcholine (PCs) are mostly decreased in the obese group; whereas most acylcarnitines

453 (C) are elevated. The metabolic changes show an overall accumulation of saturated fatty acid,
454 but repression of fat breakdown, glucose, and unsaturated fatty acid generation. As poly-
455 unsaturated fatty acids (eg. arachidonic acid) have important anti-inflammatory effects, the
456 results indicate a pro-inflammatory environment in offspring born of pre-pregnant obese
457 mothers.

458

459 **CpGs associated with maternal obesity are highly predictive of cancer states**

460 Maternal pre-pregnancy obesity might predispose a higher risk of cancer and other diseases in
461 babies' later life, via epigenetic modification^{12,17}. To check this assumption, we built maternal
462 obesity classification models using the 186 hypermethylated marker CpG sites obtained from top
463 KEGG pathways (**Supplementary Table 2**). These 186 CpG markers are from 144 genes
464 predominantly associated with cell cycle regulation, protein synthesis, and immune function. We
465 tested different classification methods including GLMNET, KNN, LOG, Random Forest (RF),
466 SVM methods, and found that the RF model yields the highest accuracy (**Supplementary**
467 **Figure 4**). We then applied this RF model to the normal adjacency and tumor tissues from DNA
468 methylation data of 14 TCGA cancers, each having sufficient tumor adjacent normal samples
469 ($n > 10$). As shown in **Figure 6A**, the averaged random forest AUC reached 0.8687 (0.7417-
470 0.9966) across all cancer datasets. Similarly, this RF model also yields high values in sensitivity,
471 specificity, and F-1 scores across cancer types (**Figure 6B**). Thus, the CpGs epigenetic markers
472 associated with maternal obesity are also strongly associated with tumorigenesis. Our result
473 supports that maternal pre-pregnancy obesity may predispose offspring to increased cancer risk
474 later in life through epigenetic modifications.

475

476

477 **Discussion**

478 Maternal obesity is one of the most urgent health concerns worldwide. Pre-pregnancy maternal
479 obesity could cause various pregnancy-related complications and predispose offspring to
480 cardiometabolic complications and chronic diseases in the long term⁹. Multiple cross-continental
481 large cohort meta-analyses have shown that maternal obesity is directly associated with
482 offspring's risk of obesity, coronary heart disease, insulin resistance, and adverse
483 neurodevelopmental outcomes based on longitudinal observational studies^{9,89,90}. To directly
484 ping-point the molecular level changes in offspring by maternal pre-pregnancy obesity, we used
485 cord blood stem cells as the studying material, which serve as a great surrogate revealing the
486 newborn's metabolism and immune system changes at the time of birth⁹¹. The current study
487 expands on previous effects and investigates the direct impact of maternal obesity on uHSCs
488 programming, the progenitor of the immune cell population, using a multi-omics (epigenetic,
489 gene expression, and metabolite) analysis approach from a unique multi-ethnic cohort.

490

491 Centered around methylation changes, three complimentary functional analysis approaches
492 (KEGG, WGCNA, and PPI) consistently demonstrated that maternal obesity impacts multiple
493 biological functions including hypermethylation in promoters of genes involved in cell cycle,
494 ribosome biogenesis, and mTOR signaling pathways. Moreover, mTOR signaling pathway also
495 plays a crucial role in metabolism and cell cycle regulation, disruption in this pathway leads to
496 insulin resistance and long-term diseases⁹². We observed a significant increase in stemness
497 scores among uHSCs affected by maternal obesity, aligning with expected downregulation in the
498 cell cycle gene expression due to observed hypermethylation in the promoters of these genes.

499 Higher stemness scores indicate enhanced quiescence, shifting the balance between stem cell
500 maintenance and differentiation towards the former. Unlike adult HSCs, fetal/neonatal HSCs
501 typically exhibit higher proliferation and self-renewal capabilities, crucial for blood cell
502 regeneration and innate immune system development⁹³. Our findings provide strong epigenetic
503 evidence that maternal obesity compromises the maturation processes in neonatal uHSCs, which
504 may predispose newborns to immunological disorders.

505
506 The subsequent multi-omics integration analysis expanded conclusions from methylation
507 analysis to additional metabolomics readouts that are also linked to biological functions eg. cell
508 cycle and inflammatory pathway. We thus propose the conceptual model to illustrate the effect
509 of maternal pre-pregnancy obesity (**Figure 7**). Maternal obesity leads to nutrient deficiency with
510 lower levels of essential amino acids and fatty acids in the newborn blood and disrupts the lipid
511 metabolism homeostasis in offspring. These metabolite changes further induce cell membrane
512 instability and repress cell cycle progression, cell proliferation⁹⁴, enhancing the dysregulation of
513 these functions preexisting at the methylation level. Lipid dysregulation may also enhance the
514 pro-inflammatory environment, which in turn induces complications in offspring later in life,
515 such as cardiovascular diseases. Such a proposed model is also consistent with and further
516 strengthens previous studies at the metabolomics or epigenome levels. For example, previous
517 metabolomics studies of cord blood showed metabolic derangement predisposes newborns to
518 cardiometabolic and endocrine diseases, and disrupt the normal hormone function and neonatal
519 adiposity^{88,95}. Previous epigenome-wide association study (EWAS) with cord blood found a
520 strong association between DNA methylation pattern and postnatal BMI trajectory until
521 adolescent⁹⁶.

522

523 Perhaps another most significant finding of this study is that it provides direct and strong
524 quantitative support to the long-speculated theory of the utero origin of cancers^{10,11}. In particular,
525 some researchers hypothesized there exist higher stem cell burdens in newborn babies born from
526 obese mothers¹². Here we provide direct evidence that such stem cell burden is highly likely due
527 to transgenerational DNA methylation modification on some key biological functions (cell cycle,
528 ribosome function, and immune response) in the uHSCs. We demonstrated this by applying a
529 random forest model using the 186 maternal obesity-associated CpG markers in uHSCs on 14
530 cancer types across thousands of samples in TCGA. The random forest model achieved high
531 classification accuracy in distinguishing between tumor and adjacent normal tissues.

532 Uncontrolled cell division, immune evasion, and chronic inflammation are well-established
533 hallmarks of cancer⁹⁷, and these featured 186 CpG sites were implicated in relevant biological
534 pathways that were intimately connected with cancer development. Aforehand results revealed a
535 significant increase in stemness scores among uHSCs affected by maternal obesity, which aligns
536 with the observed hypermethylation and subsequent downregulation of key cell cycle genes. This
537 heightened stemness may predispose these cells to malignant transformation if these epigenetic
538 modifications persist, leading to an elevated stem cell burden, disrupting normal cell cycle
539 control, weakening immune surveillance, and ultimately increasing susceptibility to cancer.

540

541 In summary, this newborn study demonstrates the direct impact of maternal pre-pregnancy
542 obesity and on newborn blood at the multi-omics level, which includes increased cell cycle
543 arrest, impairment in the uHSCs differentiation capacity, more inflammation, and disruption in
544 lipid metabolism. We also showed maternal obesity-associated epigenetic modifications are

545 closely related to cancer markers, which could potentially help mitigate the transgenerational
546 health risks.

547

548

549 **Declaration of generative AI and AI-assisted technologies in the writing process**

550 During the preparation of this work the author(s) used GPT-4.0 in order to improve the
551 readability. After using this tool/service, the author(s) reviewed and edited the content
552 thoroughly and take(s) full responsibility for the content of the publication.

553

554 **Data availability statement**

555 Data generated in this study have been submitted and will be available through the National
556 Institutes of Health Gene Expression Omnibus (GEO reviewer token available upon request).
557 Code to produce the analyses in this manuscript are available through GitHub
558 (<https://github.com/lanagarmire/>)

559

560 **Acknowledgments**

561 This research was supported by grants R01 LM012373 and LM012907 awarded by NLM, and
562 R01 HD084633 awarded by NICHD to L.X. Garmire, as well as in part by the NCI Cancer
563 Center Support Grant (CCSG) number P30 CA071789 awarded to Genomics and Bioinformatics
564 Shared Resource (RRID:SCR_019085). This research was supported in part by training funding
565 provided by the NIH grant T32 GM141746 and Advanced Proteogenomics of Cancer (T32
566 CA140044).

567

568 **Author contributions**

569 LG envisioned this project, obtained the funding, supervised the study and revised the
570 manuscript. YD performed the data analysis, generated the figures, and wrote the initial
571 manuscript. YS collected TCGA data and built the machine learning models. RS consented
572 patients and obtained the samples from the hospital, with coordination from PB. DT and SW
573 coordinated with the patient recruitment and study. PB coordinated all the multi-omics assays.
574 PB, CL, and FA designed the DNA methylation assays. AG performed FACS sorting of cord
575 blood cells. ALJ performed the Illumina Meth 450 assay, MT supervised the Genomics Shared
576 Resource analyses and provided a critical review of the manuscript. All authors have read the
577 manuscript.

578

579 **Conflicts of interest**

580 None

581

582

583 **References**

- 584 1. Leddy, M.A., Power, M.L., and Schulkin, J. (2008). The impact of maternal obesity on
585 maternal and fetal health. *Rev. Obstet. Gynecol. 1*, 170–178.
- 586 2. Hjalgrim, L.L., Westergaard, T., Rostgaard, K., Schmiegelow, K., Melbye, M., Hjalgrim,
587 H., and Engels, E.A. (2003). Birth weight as a risk factor for childhood leukemia: a meta-
588 analysis of 18 epidemiologic studies. *Am. J. Epidemiol. 158*, 724–735.
- 589 3. Harder, T., Plagemann, A., and Harder, A. (2010). Birth weight and risk of neuroblastoma:
590 a meta-analysis. *Int. J. Epidemiol. 39*, 746–756.
- 591 4. Cnattingius, S., Lundberg, F., Sandin, S., Grönberg, H., and Iliadou, A. (2009). Birth
592 characteristics and risk of prostate cancer: the contribution of genetic factors. *Cancer*
593 *Epidemiol. Biomarkers Prev. 18*, 2422–2426.

- 594 5. Eriksson, M., Wedel, H., Wallander, M.-A., Krakau, I., Hugosson, J., Carlsson, S., and
595 Svärdsudd, K. (2007). The impact of birth weight on prostate cancer incidence and
596 mortality in a population-based study of men born in 1913 and followed up from 50 to 85
597 years of age. *Prostate* 67, 1247–1254.
- 598 6. Michos, A., Xue, F., and Michels, K.B. (2007). Birth weight and the risk of testicular
599 cancer: a meta-analysis. *Int. J. Cancer* 121, 1123–1131.
- 600 7. Silva, I. dos S., De Stavola, B., McCormack, V., and Collaborative Group on Pre-Natal Risk
601 Factors and Subsequent Risk of Breast Cancer (2008). Birth size and breast cancer risk: re-
602 analysis of individual participant data from 32 studies. *PLoS Med.* 5, e193.
- 603 8. Van Cleave, J., Gortmaker, S.L., and Perrin, J.M. (2010). Dynamics of obesity and chronic
604 health conditions among children and youth. *JAMA* 303, 623–630.
- 605 9. Godfrey, K.M., Reynolds, R.M., Prescott, S.L., Nyirenda, M., Jaddoe, V.W., Eriksson, J.G.,
606 and Broekman, B.F. (2017). Influence of maternal obesity on the long-term health of
607 offspring. *The lancet. Diabetes & endocrinology* 5. [https://doi.org/10.1016/S2213-](https://doi.org/10.1016/S2213-8587(16)30107-3)
608 [8587\(16\)30107-3](https://doi.org/10.1016/S2213-8587(16)30107-3).
- 609 10. Barker, D.J. (2007). The origins of the developmental origins theory. *J. Intern. Med.* 261.
610 <https://doi.org/10.1111/j.1365-2796.2007.01809.x>.
- 611 11. Barker, D.J. (2000). In utero programming of cardiovascular disease. *Theriogenology* 53.
612 [https://doi.org/10.1016/s0093-691x\(99\)00258-7](https://doi.org/10.1016/s0093-691x(99)00258-7).
- 613 12. Qiu, L., Low, H.P., Chang, C.-I., Strohsnitter, W.C., Anderson, M., Edmiston, K., Adami,
614 H.-O., Ekblom, A., Hall, P., Ligiou, P., et al. (2012). Novel measurements of mammary
615 stem cells in human umbilical cord blood as prospective predictors of breast cancer
616 susceptibility in later life. *Ann. Oncol.* 23, 245–250.
- 617 13. Savarese, T.M., Strohsnitter, W.C., Low, H.P., Liu, Q., Baik, I., Okulicz, W., Chelmos,
618 D.P., Ligiou, P., Quesenberry, P.J., Noller, K.L., et al. (2007). Correlation of umbilical cord
619 blood hormones and growth factors with stem cell potential: implications for the prenatal
620 origin of breast cancer hypothesis. *Breast Cancer Res.* 9, R29.
- 621 14. Marshall, G.M., Carter, D.R., Cheung, B.B., Liu, T., Mateos, M.K., Meyerowitz, J.G., and
622 Weiss, W.A. (2014). The prenatal origins of cancer. *Nat. Rev. Cancer* 14, 277–289.
- 623 15. Fábíán, Á., Vereb, G., and Szöllösi, J. (2013). The hitchhikers guide to cancer stem cell
624 theory: markers, pathways and therapy. *Cytometry A* 83, 62–71.
- 625 16. Tan, B.T., Park, C.Y., Ailles, L.E., and Weissman, I.L. (2006). The cancer stem cell
626 hypothesis: a work in progress. *Lab. Invest.* 86, 1203–1207.
- 627 17. Strohsnitter, W.C., Savarese, T.M., Low, H.P., Chelmos, D.P., Ligiou, P., Lambe, M.,
628 Edmiston, K., Liu, Q., Baik, I., Noller, K.L., et al. (2008). Correlation of umbilical cord
629 blood haematopoietic stem and progenitor cell levels with birth weight: implications for a

- 630 prenatal influence on cancer risk. *Br. J. Cancer* 98, 660–663.
- 631 18. Apgar, V. (1953). A Proposal for a New Method of Evaluation of the Newborn Infant.
632 *Anesthesia & Analgesia* 32, 260.
- 633 19. Morris, T.J., Butcher, L.M., Feber, A., Teschendorff, A.E., Chakravarthy, A.R., Wojdacz,
634 T.K., and Beck, S. (2014). ChAMP: 450k Chip Analysis Methylation Pipeline.
635 *Bioinformatics* 30, 428–430.
- 636 20. Aryee, M.J., Jaffe, A.E., Corrada-Bravo, H., Ladd-Acosta, C., Feinberg, A.P., Hansen,
637 K.D., and Irizarry, R.A. (2014). Minfi: a flexible and comprehensive Bioconductor package
638 for the analysis of Infinium DNA methylation microarrays. *Bioinformatics* 30, 1363–1369.
- 639 21. Fortin, J.-P., Triche, T.J., Jr, and Hansen, K.D. (2017). Preprocessing, normalization and
640 integration of the Illumina HumanMethylationEPIC array with minfi. *Bioinformatics* 33,
641 558–560.
- 642 22. Zhou, W., Laird, P.W., and Shen, H. (2017). Comprehensive characterization, annotation
643 and innovative use of Infinium DNA methylation BeadChip probes. *Nucleic Acids Res.* 45,
644 e22.
- 645 23. Teschendorff, A.E., Marabita, F., Lechner, M., Bartlett, T., Tegner, J., Gomez-Cabrero, D.,
646 and Beck, S. (2013). A beta-mixture quantile normalization method for correcting probe
647 design bias in Illumina Infinium 450 k DNA methylation data. *Bioinformatics* 29, 189–196.
- 648 24. Du, P., Kibbe, W.A., and Lin, S.M. (2007). nuID: a universal naming scheme of
649 oligonucleotides for illumina, affymetrix, and other microarrays. *Biol. Direct* 2, 16.
- 650 25. Lin, S.M., Du, P., Huber, W., and Kibbe, W.A. (2008). Model-based variance-stabilizing
651 transformation for Illumina microarray data. *Nucleic Acids Res.* 36, e11.
- 652 26. Du, P., Kibbe, W.A., and Lin, S.M. (2008). lumi: a pipeline for processing Illumina
653 microarray. *Bioinformatics* 24, 1547–1548.
- 654 27. Du, P., Zhang, X., Huang, C.-C., Jafari, N., Kibbe, W.A., Hou, L., and Lin, S.M. (2010).
655 Comparison of Beta-value and M-value methods for quantifying methylation levels by
656 microarray analysis. *BMC Bioinformatics* 11, 587.
- 657 28. He, B., Liu, Y., Maurya, M.R., Benny, P., Lassiter, C., Li, H., Subramaniam, S., and
658 Garmire, L.X. (2021). The maternal blood lipidome is indicative of the pathogenesis of
659 severe preeclampsia. *J. Lipid Res.* 62. <https://doi.org/10.1016/j.jlr.2021.100118>.
- 660 29. Chen, Y., He, B., Liu, Y., Aung, M.T., Rosario-Pabón, Z., Vélez-Vega, C.M.,
661 Alshawabkeh, A., Cordero, J.F., Meeker, J.D., and Garmire, L.X. (2022). Maternal plasma
662 lipids are involved in the pathogenesis of preterm birth. *Gigascience* 11.
663 <https://doi.org/10.1093/gigascience/giac004>.
- 664 30. Ritchie, M.E., Phipson, B., Wu, D., Hu, Y., Law, C.W., Shi, W., and Smyth, G.K. (2015).

- 665 limma powers differential expression analyses for RNA-sequencing and microarray studies.
666 *Nucleic Acids Res.* *43*, e47.
- 667 31. Jaffe, A.E., Murakami, P., Lee, H., Leek, J.T., Fallin, M.D., Feinberg, A.P., and Irizarry,
668 R.A. (2012). Bump hunting to identify differentially methylated regions in epigenetic
669 epidemiology studies. *Int. J. Epidemiol.* *41*, 200–209.
- 670 32. Novakovic, B., Yuen, R.K., Gordon, L., Penaherrera, M.S., Sharkey, A., Moffett, A., Craig,
671 J.M., Robinson, W.P., and Saffery, R. (2011). Evidence for widespread changes in promoter
672 methylation profile in human placenta in response to increasing gestational age and
673 environmental/stochastic factors. *BMC Genomics* *12*. [https://doi.org/10.1186/1471-2164-](https://doi.org/10.1186/1471-2164-12-529)
674 [12-529](https://doi.org/10.1186/1471-2164-12-529).
- 675 33. GEO Accession viewer <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE36829>.
- 676 34. Chu, T., Bunce, K., Shaw, P., Shridhar, V., Althouse, A., Hubel, C., and Peters, D. (2014).
677 Comprehensive analysis of preeclampsia-associated DNA methylation in the placenta.
678 *PLoS One* *9*. <https://doi.org/10.1371/journal.pone.0107318>.
- 679 35. Blair, J.D., Yuen, R.K., Lim, B.K., McFadden, D.E., von Dadelszen, P., and Robinson,
680 W.P. (2013). Widespread DNA hypomethylation at gene enhancer regions in placentas
681 associated with early-onset pre-eclampsia. *Mol. Hum. Reprod.* *19*.
682 <https://doi.org/10.1093/molehr/gat044>.
- 683 36. Hanna, C.W., Peñaherrera, M.S., Saadeh, H., Andrews, S., McFadden, D.E., Kelsey, G.,
684 and Robinson, W.P. (2016). Pervasive polymorphic imprinted methylation in the human
685 placenta. *Genome Res.* *26*. <https://doi.org/10.1101/gr.196139.115>.
- 686 37. Blair, J.D., Langlois, S., McFadden, D.E., and Robinson, W.P. (2014). Overlapping DNA
687 methylation profile between placentas with trisomy 16 and early-onset preeclampsia.
688 *Placenta* *35*. <https://doi.org/10.1016/j.placenta.2014.01.001>.
- 689 38. Price, E.M., Peñaherrera, M.S., Portales-Casamar, E., Pavlidis, P., Van Allen, M.I.,
690 McFadden, D.E., and Robinson, W.P. (2016). Profiling placental and fetal DNA
691 methylation in human neural tube defects. *Epigenetics Chromatin* *9*.
692 <https://doi.org/10.1186/s13072-016-0054-8>.
- 693 39. Leavey, K., Wilson, S.L., Bainbridge, S.A., Robinson, W.P., and Cox, B.J. (2018).
694 Epigenetic regulation of placental gene expression in transcriptional subtypes of
695 preeclampsia. *Clin. Epigenetics* *10*. <https://doi.org/10.1186/s13148-018-0463-6>.
- 696 40. Wilson, S.L., Leavey, K., Cox, B.J., and Robinson, W.P. (2018). Mining DNA methylation
697 alterations towards a classification of placental pathologies. *Hum. Mol. Genet.* *27*.
698 <https://doi.org/10.1093/hmg/ddx391>.
- 699 41. Hansen, K.D. IlluminaHumanMethylation450kanno. ilmn12. hg19: annotation for
700 Illumina's 450k methylation arrays. R package version 0.6. 0.

- 701 42. Maksimovic, J., Gordon, L., and Oshlack, A. (2012). SWAN: Subset-quantile within array
702 normalization for illumina infinium HumanMethylation450 BeadChips. *Genome Biol.* *13*,
703 R44.
- 704 43. Phipson, B., and Oshlack, A. (2014). DiffVar: a new method for detecting differential
705 variability with application to methylation in cancer and aging. *Genome Biol.* *15*, 465.
- 706 44. Maksimovic, J., Gagnon-Bartsch, J.A., Speed, T.P., and Oshlack, A. (2015). Removing
707 unwanted variation in a differential methylation analysis of Illumina HumanMethylation450
708 array data. *Nucleic Acids Res.* *43*, e106.
- 709 45. Phipson, B., Maksimovic, J., and Oshlack, A. (2016). missMethyl: an R package for
710 analyzing data from Illumina's HumanMethylation450 platform. *Bioinformatics* *32*, 286–
711 288.
- 712 46. Kanehisa, M., and Goto, S. (2000). KEGG: kyoto encyclopedia of genes and genomes.
713 *Nucleic Acids Res.* *28*, 27–30.
- 714 47. Kanehisa, M. (2019). Toward understanding the origin and evolution of cellular organisms.
715 *Protein Sci.* *28*, 1947–1951.
- 716 48. Kanehisa, M., Furumichi, M., Sato, Y., Kawashima, M., and Ishiguro-Watanabe, M. (2022).
717 KEGG for taxonomy-based analysis of pathways and genomes. *Nucleic Acids Res.*
718 <https://doi.org/10.1093/nar/gkac963>.
- 719 49. Langfelder, P., and Horvath, S. (2008). WGCNA: an R package for weighted correlation
720 network analysis. *BMC Bioinformatics* *9*, 559.
- 721 50. Langfelder, P., and Horvath, S. (2012). Fast R Functions for Robust Correlations and
722 Hierarchical Clustering. *J. Stat. Softw.* *46*. <https://doi.org/10.18637/jss.v046.i11>.
- 723 51. Szklarczyk, D., Gable, A.L., Nastou, K.C., Lyon, D., Kirsch, R., Pyysalo, S., Doncheva,
724 N.T., Legeay, M., Fang, T., Bork, P., et al. (2021). The STRING database in 2021:
725 customizable protein-protein networks, and functional characterization of user-uploaded
726 gene/measurement sets. *Nucleic Acids Res.* *49*, D605–D612.
- 727 52. Li, H., Tong, P., Gallegos, J., Dimmer, E., Cai, G., Molldrem, J.J., and Liang, S. (2015).
728 PAND: A Distribution to Identify Functional Linkage from Networks with Preferential
729 Attachment Property. *PLoS One* *10*, e0127968.
- 730 53. Shannon, P., Markiel, A., Ozier, O., Baliga, N.S., Wang, J.T., Ramage, D., Amin, N.,
731 Schwikowski, B., and Ideker, T. (2003). Cytoscape: a software environment for integrated
732 models of biomolecular interaction networks. *Genome Res.* *13*, 2498–2504.
- 733 54. He, B., and Garmire, L.X. (2021). ASGARD: A Single-cell Guided pipeline to Aid
734 Repurposing of Drugs. *ArXiv*.
- 735 55. MacArthur, B.D., and Lemischka, I.R. (2013). Statistical mechanics of pluripotency. *Cell*

- 736 154, 484–489.
- 737 56. Martínez, O., and Reyes-Valdés, M.H. (2008). Defining diversity, specialization, and gene
738 specificity in transcriptomes through information theory. *Proc. Natl. Acad. Sci. U. S. A.*
739 *105*, 9709–9714.
- 740 57. Kannan, S., Farid, M., Lin, B.L., Miyamoto, M., and Kwon, C. (2021). Transcriptomic
741 entropy benchmarks stem cell-derived cardiomyocyte maturation against endogenous tissue
742 at single cell level. *PLoS Comput. Biol.* *17*, e1009305.
- 743 58. Bushnell, B. (2014). BBMap: A Fast, Accurate, Splice-Aware Aligner.
- 744 59. Andrews, S. FastQC: a quality control tool for high throughput sequence data. Available
745 online. Retrieved May.
- 746 60. Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P.,
747 Chaisson, M., and Gingeras, T.R. (2013). STAR: ultrafast universal RNA-seq aligner.
748 *Bioinformatics* *29*, 15–21.
- 749 61. Liao, Y., Smyth, G.K., and Shi, W. (2014). featureCounts: an efficient general purpose
750 program for assigning sequence reads to genomic features. *Bioinformatics* *30*, 923–930.
- 751 62. Liao, Y., Smyth, G.K., and Shi, W. (2013). The Subread aligner: fast, accurate and scalable
752 read mapping by seed-and-vote. *Nucleic Acids Res.* *41*, e108.
- 753 63. Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and
754 dispersion for RNA-seq data with DESeq2. *Genome Biol.* *15*, 550.
- 755 64. Chen, J., Xu, H., Aronow, B.J., and Jegga, A.G. (2007). Improved human disease candidate
756 gene prioritization using mouse phenotype. *BMC Bioinformatics* *8*, 392.
- 757 65. Chen, J., Aronow, B.J., and Jegga, A.G. (2009). Disease candidate gene identification and
758 prioritization using protein interaction networks. *BMC Bioinformatics* *10*, 73.
- 759 66. Chen, J., Bardes, E.E., Aronow, B.J., and Jegga, A.G. (2009). ToppGene Suite for gene list
760 enrichment analysis and candidate gene prioritization. *Nucleic Acids Res.* *37*, W305–W311.
- 761 67. Schlueter, R.J., Al-Akwaa, F.M., Benny, P.A., Gurary, A., Xie, G., Jia, W., Chun, S.J.,
762 Chern, I., and Garmire, L.X. (2020). Pregnant Obesity of Mothers in a Multiethnic
763 Cohort Is Associated with Cord Blood Metabolomic Changes in Offspring. *J. Proteome*
764 *Res.* *19*, 1361–1374.
- 765 68. Johnson, W.E., Li, C., and Rabinovic, A. (2006). Adjusting batch effects in microarray
766 expression data using empirical Bayes methods. *Biostatistics* *8*, 118–127.
- 767 69. Singh, A., Shannon, C.P., Gautier, B., Rohart, F., Vacher, M., Tebbutt, S.J., and Cao, K.-
768 A.L. (2019). DIABLO: an integrative approach for identifying key molecular drivers from
769 multi-omics assays. *Bioinformatics* *35*, 3055.

- 770 70. Luo, W., and Brouwer, C. (2013). Pathview: an R/Bioconductor package for pathway-based
771 data integration and visualization. *Bioinformatics* 29, 1830–1831.
- 772 71. Kuhn, M. (2008). Building Predictive Models in R Using the caret Package. *J. Stat. Softw.*
773 28, 1–26.
- 774 72. Fang, X., Liu, Y., Ren, Z., Du, Y., Huang, Q., and Garmire, L.X. (2021). Lilikoi V2.0: a
775 deep learning-enabled, personalized pathway-based R package for diagnosis and prognosis
776 predictions using metabolomics data. *Gigascience* 10.
777 <https://doi.org/10.1093/gigascience/giaa162>.
- 778 73. Heard, E., and Martienssen, R.A. (2014). Transgenerational epigenetic inheritance: myths
779 and mechanisms. *Cell* 157, 95–109.
- 780 74. King, S.E., and Skinner, M.K. (2020). Epigenetic Transgenerational Inheritance of Obesity
781 Susceptibility. *Trends Endocrinol. Metab.* 31, 478–494.
- 782 75. Morisako, A.K., Tauali‘i, M., Ambrose, A.J.H., and Withy, K. (2017). Beyond the Ability
783 to Pay: The Health Status of Native Hawaiians and Other Pacific Islanders in Relationship
784 to Health Insurance. *Hawaii J. Med. Public Health* 76, 36.
- 785 76. Heslehurst, N., Vieira, R., Akhter, Z., Bailey, H., Slack, E., Ngongalah, L., Pemu, A., and
786 Rankin, J. (2019). The association between maternal body mass index and child obesity: A
787 systematic review and meta-analysis. *PLoS Med.* 16, e1002817.
- 788 77. Liu, W., Yang, X., Mao, Z., Du, Y., Lassiter, C., AlAkwa, F.M., Benny, P.A., and
789 Garmire, L.X. Severe preeclampsia is not associated with significant DNA methylation
790 changes but cell proportion changes in the cord blood - caution on the importance of
791 confounding adjustment. medRxiv. <https://doi.org/10.1101/2023.08.31.23294898>.
- 792 78. Abu-Farha, M., Tiss, A., Abubaker, J., Khadir, A., Al-Ghimlas, F., Al-Khairi, I., Baturcam,
793 E., Cherian, P., Elkum, N., Hammad, M., et al. (2013). Proteomics Analysis of Human
794 Obesity Reveals the Epigenetic Factor HDAC4 as a Potential Target for Obesity. *PLoS One*
795 8. <https://doi.org/10.1371/journal.pone.0075342>.
- 796 79. Rönn, T., Volkov, P., Gillberg, L., Kokosar, M., Perfilyev, A., Jacobsen, A.L., Jørgensen,
797 S.W., Brøns, C., Jansson, P.A., Eriksson, K.F., et al. (2015). Impact of age, BMI and
798 HbA1c levels on the genome-wide DNA methylation and mRNA expression patterns in
799 human adipose tissue and identification of epigenetic biomarkers in blood. *Hum. Mol.*
800 *Genet.* 24. <https://doi.org/10.1093/hmg/ddv124>.
- 801 80. Lim, W.-J., Kim, K.H., Kim, J.-Y., Jeong, S., and Kim, N. (2019). Identification of DNA-
802 Methylated CpG Islands Associated With Gene Silencing in the Adult Body Tissues of the
803 Ogye Chicken Using RNA-Seq and Reduced Representation Bisulfite Sequencing. *Front.*
804 *Genet.* 10, 346.
- 805 81. Ching, T., Song, M.-A., Tiirikainen, M., Molnar, J., Berry, M., Towner, D., and Garmire,
806 L.X. (2014). Genome-wide hypermethylation coupled with promoter hypomethylation in

- 807 the chorioamniotic membranes of early onset pre-eclampsia. *Mol. Hum. Reprod.* *20*, 885–
808 904.
- 809 82. Meng, D., Frank, A.R., and Jewell, J.L. (2018). mTOR signaling in stem and progenitor
810 cells. *Development* *145*. <https://doi.org/10.1242/dev.152595>.
- 811 83. Guo, M., Bao, E.L., Wagner, M., Whitsett, J.A., and Xu, Y. (2017). SLICE: determining
812 cell differentiation and lineage based on single cell entropy. *Nucleic Acids Res.* *45*, e54.
- 813 84. Dai, D., Li, L., Huebner, A., Zeng, H., Guevara, E., Claypool, D.J., Liu, A., and Chen, J.
814 (2012). Planar cell polarity effector gene *Intu* regulates cell fate-specific differentiation of
815 keratinocytes through the primary cilia. *Cell Death Differ.* *20*, 130–138.
- 816 85. Liu, J., and Fuchs, S.Y. (2006). Cross-talk between APC/C and CBP/p300. *Cancer Biol.*
817 *Ther.* *5*. <https://doi.org/10.4161/cbt.5.7.3103>.
- 818 86. Corbi, S.C.T., Bastos, A.S., Nepomuceno, R., Cirelli, T., Dos Santos, R.A., Takahashi, C.S.,
819 Rocha, C.S., Orrico, S.R.P., Maurer-Morelli, C.V., and Scarel-Caminaga, R.M. (2017).
820 Expression Profile of Genes Potentially Associated with Adequate Glycemic Control in
821 Patients with Type 2 Diabetes Mellitus. *Journal of diabetes research* *2017*.
822 <https://doi.org/10.1155/2017/2180819>.
- 823 87. Behl, T., Kaur, I., Sehgal, A., Singh, S., Zengin, G., Negrut, N., Nistor-Cseppento, D.C.,
824 Pavel, F.M., Aron, R.A.C., and Bungau, S. (2021). Exploring the Genetic Conception of
825 Obesity via the Dual Role of FoxO. *Int. J. Mol. Sci.* *22*.
826 <https://doi.org/10.3390/ijms22063179>.
- 827 88. Kadakia, R., Zheng, Y., Zhang, Z., Zhang, W., Hou, L., and Josefson, J.L. (2017). Maternal
828 pre-pregnancy BMI downregulates neonatal cord blood LEP methylation. *Pediatr. Obes.* *12*
829 *Suppl 1*, 57–64.
- 830 89. Yu, Z., Han, S., Zhu, J., Sun, X., Ji, C., and Guo, X. (2013). Pre-pregnancy body mass
831 index in relation to infant birth weight and offspring overweight/obesity: a systematic
832 review and meta-analysis. *PLoS One* *8*, e61627.
- 833 90. Sureshchandra, S., Marshall, N.E., and Messaoudi, I. (2019). Impact of pregravid obesity on
834 maternal and fetal immunity: Fertile grounds for reprogramming. *J. Leukoc. Biol.* *106*,
835 1035–1050.
- 836 91. Levy, O. (2005). Innate immunity of the human newborn: distinct cytokine responses to
837 LPS and other Toll-like receptor agonists. *J. Endotoxin Res.* *11*, 113–116.
- 838 92. Ong, P.S., Wang, L.Z., Dai, X., Tseng, S.H., Loo, S.J., and Sethi, G. (2016). Judicious
839 Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence
840 and Perspectives. *Front. Pharmacol.* *7*. <https://doi.org/10.3389/fphar.2016.00395>.
- 841 93. Mack, R., Zhang, L., Breslin, P., and Zhang, J. (2021). The fetal-to-adult hematopoietic
842 stem cell transition and its role in childhood hematopoietic malignancies. *Stem cell reviews*

- 843 and reports *17*, 2059.
- 844 94. Kwok, A.C., and Wong, J.T. (2005). Lipid biosynthesis and its coordination with cell cycle
845 progression. *Plant Cell Physiol.* *46*. <https://doi.org/10.1093/pcp/pci213>.
- 846 95. Denizli, M., Capitano, M.L., and Kua, K.L. (2022). Maternal obesity and the impact of
847 associated early-life inflammation on long-term health of offspring. *Front. Cell. Infect.*
848 *Microbiol.* *12*, 940937.
- 849 96. Meir, A.Y., Huang, W., Cao, T., Hong, X., Wang, G., Pearson, C., Adams, W.G., Wang, X.,
850 and Liang, L. (2023). Umbilical cord DNA methylation is associated with body mass index
851 trajectories from birth to adolescence. *EBioMedicine* *91*, 104550.
- 852 97. Hanahan, D., and Weinberg, R.A. (2011). Hallmarks of Cancer: The Next Generation. *Cell*
853 *144*, 646–674.
- 854 98. O’Flaherty, J.D., Barr, M., Fennell, D., Richard, D., Reynolds, J., O’Leary, J., and O’Byrne,
855 K. (2012). The cancer stem-cell hypothesis: its emerging role in lung cancer biology and its
856 relevance for future therapy. *J. Thorac. Oncol.* *7*, 1880–1890.
- 857 99. Oesterreich, S., Allredl, D.C., Mohsin, S.K., Zhang, Q., Wong, H., Lee, A.V., Osborne,
858 C.K., and O’Connell, P. (2001). High rates of loss of heterozygosity on chromosome 19p13
859 in human breast cancer. *Br. J. Cancer* *84*, 493–498.
- 860 100. Hong, E.A., Gautrey, H.L., Elliott, D.J., and Tyson-Capper, A.J. (2012). SAFB1- and
861 SAFB2-mediated transcriptional repression: relevance to cancer. *Biochem. Soc. Trans.* *40*,
862 826–830.
- 863 101. Hammerich-Hille, S., Kaiparettu, B.A., Tsimelzon, A., Creighton, C.J., Jiang, S., Polo,
864 J.M., Melnick, A., Meyer, R., and Oesterreich, S. (2010). SAFB1 mediates repression of
865 immune regulators and apoptotic genes in breast cancer cells. *J. Biol. Chem.* *285*, 3608–
866 3616.
- 867
- 868

869 **Figure legends**

870

871 **Figure 1. Overview of the study design and analysis.** In the preparation step, cord blood
872 plasma samples are collected for metabolome profiling and stem cell sorting. DNA and RNA
873 extraction assays are performed on the enriched stem cells for the methylation and RNA-seq
874 analyses. Downstream analyses are mainly focused on the methylation data. Bulk RNA-seq data
875 were used for validations for methylation discoveries. (Created with BioRender.com)

876

877 **Figure 2. Mother and newborns statistics of the multi-ethnic cohort from Hawaii. (A-E)**
878 Categorical variables including baby sex, maternal ethnicity, paternal ethnicity, parity and
879 gravidity between control and obese groups are shown in the barplots. P-values using Chi-square
880 test are annotated comparing control and obese groups. **(F-I)** The distributions of maternal age,
881 gestation age, maternal net weight gain during pregnancy, and maternal hemoglobin between
882 control and obese groups are compared. Mean and standard deviation are shown in boxplot. P-
883 values using t-test are annotated. **(J-M)** The distributions of baby weight, baby head
884 circumference, baby length, and APGAR score after 5 minutes of delivery between control and
885 obese groups are compared. Mean and standard deviation are shown in boxplot. P-values using t-
886 test are annotated.

887

888 **Figure 3. DNA methylation analysis on uHSCs.**

889 **(A-B)** Source of variance plot before and after confounding adjustment. F-statistics are reported
890 for each clinical factor. F statistics greater than 1 are considered to have confounding effects in
891 addition to the case/control difference due to pre-pregnancy maternal obesity. **(C)** Volcano plot

892 of $-\log(\text{BH adjusted p-values})$ against $\log\text{FC}$. The cutoff line for adjusted p-value < 0.05 is
893 shown as the red horizontal line. The hyper/hypo threshold is shown as a blue vertical line where
894 $\log\text{FC}=0$. Non-significant methylation CpG sites after the differential analysis were shown in
895 gray. Significant CpG sites are colored. After the removal of gestational age-related CpG sites,
896 10,254 CpG sites are hypermethylated and 5,394 sites are hypomethylated. **(D-E)** Normalized
897 location distribution of differentially methylated CpG sites according to their CpG features in
898 terms of isle regions and gene regions based on the chip annotation. Isle regions include shelf,
899 shore, island, and open-sea. Gene regions include gene body, intergenic region (IGR), TSS200,
900 TSS1500, 5'UTR, 3'UTR, and 1st Exon.

901

902 **Figure 4. Pathway and network analysis.** **(A)** KEGG pathway enrichment for
903 hypermethylated CpG sites from promotor region. Enriched KEGG pathway names, adjusted p-
904 values ($-\log_{10}$ transformed), and the size of enriched gene list are reported for CpG sites from
905 TSS200+TSS1500 regions. The red dotted line shows the threshold cutoff for FDR at -
906 $\log_{10}(0.05)$. **(B-C)** Violin plots of averaged beta values for KEGG protein pathway collection
907 and immune pathway collection with Wilcoxon P-values. **(D)** Violin plots of cell entropy scores
908 between control and obese groups with Wilcoxon P-values. **(E-F)** WGCNA network analysis
909 results. WGCNA modules are shown for both the control and the obese group. The top two
910 modules with largest degrees are turquoise and brown modules. Each node represents a gene.
911 Genes co-expressed in each module are annotated. **(G)** Protein-protein interaction (PPI) network.
912 Bipartite graphs represent enriched KEGG pathways and associated genes with significant PPIs.
913 Red nodes represent genes with hypermethylated CpG sites. Blue nodes represent genes with
914 hypomethylated CpG sites. Yellow nodes represented the enriched KEGG pathways. Number of

915 inter-pathway PPIs are annotated in the rectangular boxes.

916

917 **Figure 5. Multi-omics integration analysis**

918 (A-C) Omics-specific sample plots from DIABLO showing the separation of obese and control

919 samples in methylation data, gene expression data, and metabolomics data respectively. (D-F)

920 Importance plot of top 25 features in methylation, gene expression and metabolomics modalities

921 with the highest loadings extracted from the embedding space. The color represents the condition

922 which features contribute the most.

923

924 **Figure 6. TCGA cancer classification model with maternal obesity markers**

925 (A) Receiver operating characteristic (ROC) curves of 14 TCGA random forest models built

926 with maternal pre-pregnancy obesity associated CpG markers on testing datasets. Area under the

927 curve (AUC) scores are annotated for each cancer type. (B) Random forest classification models

928 performances (AUC, Sensitivity, Specificity, and F1) on testing datasets. Mean and standard

929 deviation of the evaluation metrics are calculated over iterations.

930

931

932 **Figure 7. A proposed model of maternal obesity's impact on neonatal development.**

933

934

935

936

937

938 **Tables**

939 **Table 1. Summary statistics of the study cohort.**

		Control (n=38)	Case (n=34)
Maternal Age		31.3±5.6	31.6±4.9
Gestational Week		38.9±0.5	39.0±0.3
Net Weight Gain		32.0±11.6	30.9±14.6
Hemoglobin		11.6±1.6	11.0±1.4
Maternal Ethnicity	Asian	21	8
	Caucasian	11	4
	NHPI	6	22
Paternal Ethnicity	Asian	19	11
	Caucasian	11	2
	NHPI	8	21
Baby Sex	Female	17	21
	Male	21	13
Parity	0	7	3
	1	21	7
	2	9	11
	More	1	13
Gravidity	1	6	2
	2	15	5
	3	13	8
	4	3	6
	5	1	4
	More	0	9

940 Demographic and clinical statistics are reported for the control and maternally obese groups.

941 **Table 2. Top 20 hypermethylated CpG sites and top 20 hypomethylated CpG sites.**

CpG	Gene	Island	Group	logFC	P.Value	adj.P.Val	Type
cg12303247	SYT11	OpenSea	3'UTR	2.188	2.44E-05	6.09E-03	Hyper
cg16818768	PSMG1	Island	TSS1500	1.605	2.15E-05	5.74E-03	Hyper
cg05995465	HDAC4	OpenSea	5'UTR	1.604	1.65E-03	4.65E-02	Hyper
cg01937701	DHRS4	Island	TSS200	1.592	1.96E-10	2.45E-05	Hyper
cg22243583	DLEU1	S_Shore	Body	1.522	2.53E-06	2.01E-03	Hyper
cg16927136	RPL35A	OpenSea	TSS1500	1.507	2.39E-10	2.45E-05	Hyper
cg08899199	ST7	S_Shore	Body	1.4	7.34E-07	1.13E-03	Hyper
cg05054115	DHRS4	Island	TSS200	1.389	6.66E-08	3.73E-04	Hyper
cg12878710	LRCH3	Island	TSS200	1.387	1.27E-06	1.48E-03	Hyper
cg05130022	HMG4	N_Shore	TSS200	1.386	1.51E-04	1.45E-02	Hyper
cg05643303	HOXC8	Island	TSS200	1.345	2.70E-05	6.34E-03	Hyper
cg07449543	CHORDC1	S_Shore	TSS200	1.342	6.32E-05	9.53E-03	Hyper
cg25016112	DENND3	OpenSea	Body	1.314	1.22E-03	4.01E-02	Hyper
cg09552166	MSL2	N_Shore	TSS200	1.296	2.30E-05	5.92E-03	Hyper
cg01003902	SAFB2	Island	TSS200	1.269	1.04E-08	1.42E-04	Hyper
cg11028445	FAM96A	N_Shore	TSS1500	1.265	1.97E-04	1.65E-02	Hyper

cg10317138	ADAM12	N_Shore	Body	1.229	5.06E-04	2.60E-02	Hyper
cg09757277	ZNF222	S_Shore	5'UTR	1.229	9.88E-08	4.27E-04	Hyper
cg04117338	CRADD	N_Shore	5'UTR	1.209	1.66E-03	4.67E-02	Hyper
cg07354583	CD69	OpenSea	Body	1.205	5.94E-07	1.02E-03	Hyper
cg04043455	EBF3	S_Shelf	Body	-2.031	6.12E-04	0.029	Hypo
cg20784950	PLEC1	N_Shore	Body	-1.812	1.96E-05	0.005	Hypo
cg09976051	AGA	N_Shore	Body	-1.516	1.67E-04	0.015	Hypo
cg13862711	LHX6	Island	Body	-1.469	1.65E-03	0.047	Hypo
cg16434331	SLC39A11	OpenSea	Body	-1.411	9.52E-08	0	Hypo
cg05636467	EBF3	S_Shelf	Body	-1.335	1.65E-03	0.047	Hypo
cg16858146	TAF3	S_Shelf	Body	-1.33	3.15E-05	0.007	Hypo
cg24796644	MDGA1	Island	Body	-1.242	1.48E-05	0.005	Hypo
cg11064039	PRKAR1B	Island	5'UTR	-1.227	1.58E-03	0.046	Hypo
cg06833656	TBCD	OpenSea	Body	-1.219	2.68E-06	0.002	Hypo
cg25430507	NXPH2	S_Shore	TSS1500	-1.152	2.08E-06	0.002	Hypo
cg03485608	NXPH2	N_Shore	Body	-1.152	2.72E-06	0.002	Hypo
cg00928596	MIR365-1	OpenSea	TSS200	-1.148	7.32E-05	0.01	Hypo
cg12601963	NCRNA00200	Island	Body	-1.132	2.58E-06	0.002	Hypo

cg22772691	SLC12A7	S_Shelf	Body	-1.123	1.79E-04	0.016	Hypo
cg02584267	EBF3	OpenSea	Body	-1.121	2.39E-04	0.018	Hypo
cg19282259	NCRNA00200	Island	TSS200	-1.104	3.49E-06	0.002	Hypo
cg08010094	NXPH2	S_Shore	TSS1500	-1.094	1.04E-03	0.037	Hypo
cg06916001	MIR365-1	OpenSea	TSS200	-1.088	5.74E-05	0.009	Hypo
cg03721387	KRTAP24-1	OpenSea	3'UTR	-1.04	4.29E-06	0.003	Hypo

942 logFC, p-values, BH adjusted p-values, and CpG annotations are reported for the top 20 differentially hypermethylated CpG sites
 943 ordered by the adjusted p-values by 'limma' packages. Hypermethylated CpG sites are defined as logFC>0, whereas hypomethylated
 944 CpG sites are defined as logFC<0.

945

946

947

948


949

950

951




Cohort Collection and Sample Preparation

medRxiv preprint doi: <https://doi.org/10.1101/2024.07.27.24310936>; this version posted August 13, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).




Created with BioRender.com

1 Methylation Analyses






2 Multiomics Integration






Downstream Analyses






Enriched Stem Cells








Plasma







Molecular Profiling










A RF Testing ROC**Data**






- BLCA
- KIRC
- PAAD
- BRCA
- KIRP
- PRAD
- COAD
- LIHC
- THCA
- ESCA
- LUAD
- UCEC
- HNSC
- LUSC

B TCGA-BLCA**C** TCGA-KIRC**D** TCGA-PAAD**E** TCGA-BRCA**Metric**

- Accuracy
- Sensitivity
- Specificity
- F1

F TCGA-KIRP**G** TCGA-PRAD**H** TCGA-COAD**I** TCGA-LIHC**J** TCGA-THCA**Metric**

- Accuracy
- Sensitivity
- Specificity
- F1

K TCGA-ESCA**L** TCGA-LUAD**M** TCGA-UCEC**N** TCGA-HNSC**O** TCGA-LUSC**Metric**

- Accuracy
- Sensitivity
- Specificity
- F1

Maternal obesity

Lipid Metabolism
(PC aa/ae, Oleic acid)

Nutrient Deficiency
(DHA)

**Pro-inflammatory
Responses & Immunity**

**Membrane
damage**

**Cell cycle
repression**

Increased uHSC quiescence

**Oxidative
Stress**

**Increased
apoptosis**